Cilest Tablets
Ethinyloestradiol, Norgestimate
"35mcg, 250mcg"
Janssen-Cilag AG
| Pack size | 21's Blister |
|---|---|
| Dispensing mode | PhOM |
| Source | SWITZERLAND |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 16.00 AED |
Available as:
Indications
Cilest Tablets is used for:
ETHINYL ESTRADIOL
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive
NORGESTIMATE
For the prevention of pregnancy
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive
NORGESTIMATE
For the prevention of pregnancy
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ethinyloestradiol, Norgestimate :
Mechanism of Action
ETHINYL ESTRADIOL
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (shbg), thyroid-binding globulin (tbg), and other serum proteins and suppress follicle-stimulating hormone (fsh) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (gnrh)
NORGESTIMATE
Norgestimate binds to androgen and progestogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like norgestimate will slow the frequency of release of gonadotropin releasing hormone (gnrh) from the hypothalamus and blunt the pre-ovulatory lh (luteinizing hormone) surge
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (shbg), thyroid-binding globulin (tbg), and other serum proteins and suppress follicle-stimulating hormone (fsh) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (gnrh)
NORGESTIMATE
Norgestimate binds to androgen and progestogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like norgestimate will slow the frequency of release of gonadotropin releasing hormone (gnrh) from the hypothalamus and blunt the pre-ovulatory lh (luteinizing hormone) surge
Note
Cilest "35mcg, 250mcg" Tablets manufactured by Janssen-Cilag AG. Its generic name is Ethinyloestradiol, Norgestimate. Cilest is availble in United Arab Emirates.
Farmaco UAE drug index information on Cilest Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.